Fibrosis 4 (FIB4) scoring system based on routine laboratory tests is widely used to estimate the amount of liver fibrosis in NAFLD and help identify patients that would require further evaluation with a liver biopsy. Liver stiffness measurement (LSM) using vibration controlled transient elastography by Fibroscan is a novel non-invasive tool and currently available in the United States for assessment of liver fibrosis in patients with Abiraterone chronic liver disease. Aim: The aim of the current study is to determine the diagnostic accuracy

of FIB4 and LSM for prediction of clinically significant fibrosis in patients with NAFLD and also examine the relationship between FIB4 score and LSM.

Methods: Patients with biopsy proven NAFLD (duration between liver biopsy and Fibroscan <1 year) or NASH related cirrhosis were identified from an IRB approved prospective database of patients undergoing Fibroscan. Clinically significant fibrosis was defined as presence of clinically obvious cirrhosis or METAVIR Fibrosis stage of ≥ 2. Results: A total of 94 patients met study inclusion criteria from a total of 217 NAFLD STI571 in vivo patients that underwent Fibroscan. The mean age of the study cohort was 54 ± 10 years (60% woman; 94% Caucasian) with a BMI of 31 ± 12 kg/m2. The mean ALT was 49 ± 36 U/L. Clinically significant fibrosis was present in 70% (n=66)

of the study cohort. The diagnostic accuracy of LSM for clinically significant fibrosis was good (AUROC=0.81) while the diagnostic accuracy of FIB4 score was poor (AUROC=0.63) (Figure 1). The optimal LSM cut-off value for a diagnosis of clinically significant fibrosis was 10.3 medchemexpress kPa with a sensitivity of 80% and specificity of 75%. The correlation between LSM and FIB score was weak but significant (r=0.35, p-val=0.001). Conclusion: LSM as measured by Fibroscan could be a useful tool for prediction of clinically significant fibrosis and appears to be superior to currently used FIB4 score. AUROC curves for LSM and FIB4 for clinically significant fibrosis in NAFLD Disclosures: Naga P. Chalasani – Consulting: Salix, Abbvie, Lilly, Boerhinger-Ingelham, Aege-rion; Grant/Research Support: Intercept, Lilly, Gilead, Cumberland, Galectin The following people have nothing to disclose: Raj Vuppalanchi, Samer Gaw-rieh, Regina Weber Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease in Western countries, may progress to cirrhosis, liver failure, and complicated hepatocellular carcinoma.